share_log

Allspring Global Investments Holdings LLC Boosts Stock Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Allspring Global Investments Holdings LLC Boosts Stock Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

全春全球投資控股有限責任公司提升生物生活解決方案公司的股票地位 (NASDAQ: BLFS)
Defense World ·  2023/02/03 04:31

Allspring Global Investments Holdings LLC grew its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) by 802.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,218 shares of the medical equipment provider's stock after buying an additional 1,083 shares during the period. Allspring Global Investments Holdings LLC's holdings in BioLife Solutions were worth $27,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

根據新浪納斯達克提交給美國證券交易委員會(SEC)的最新文件,該公司第三季度持有的生物生命解決方案公司(BLFS-GET Rating)股票增加了802.2%。該基金持有這家醫療設備提供商的1,218股股票,在此期間又購買了1,083股。截至最近向美國證券交易委員會(Securities and Exchange Commission,美國證券交易委員會)提交的文件,AllSpring Global Investments Holdings LLC持有的BioLife Solutions價值27,000美元。

Several other institutional investors and hedge funds have also made changes to their positions in BLFS. Wipfli Financial Advisors LLC purchased a new stake in BioLife Solutions during the third quarter worth approximately $29,000. Point72 Hong Kong Ltd acquired a new stake in BioLife Solutions during the first quarter worth approximately $36,000. Lazard Asset Management LLC purchased a new stake in shares of BioLife Solutions during the 1st quarter worth approximately $45,000. Ancora Advisors LLC acquired a new position in shares of BioLife Solutions in the 1st quarter valued at $90,000. Finally, KBC Group NV purchased a new position in shares of BioLife Solutions in the 2nd quarter valued at $36,000. 89.82% of the stock is owned by institutional investors and hedge funds.

其他幾家機構投資者和對衝基金也改變了他們在BLFS的頭寸。Wipfli Financial Advisors LLC在第三季度購買了BioLife Solutions的新股份,價值約2.9萬美元。Point72 Hong Kong Ltd在第一季度收購了BioLife Solutions價值約36,000美元的新股份。Lazard Asset Management LLC在第一季度購買了BioLife Solutions的新股份,價值約4.5萬美元。Ancora Advisors LLC在第一季度收購了BioLife Solutions的新頭寸,價值90,000美元。最後,KBC Group NV在第二季度購買了BioLife Solutions的新頭寸,價值3.6萬美元。89.82%的股票由機構投資者和對衝基金持有。

Get
到達
BioLife Solutions
生物生命解決方案
alerts:
警報:

BioLife Solutions Price Performance

BioLife解決方案性價比

Shares of NASDAQ:BLFS opened at $25.27 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.76 and a current ratio of 3.68. BioLife Solutions, Inc. has a one year low of $10.40 and a one year high of $29.92. The company has a 50-day simple moving average of $20.72 and a 200-day simple moving average of $21.60. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -10.19 and a beta of 1.86.

納斯達克:BLFS上週五開盤報25.27美元。該公司的負債權益比率為0.06,速動比率為2.76,流動比率為3.68。BioLife Solutions,Inc.的一年低點為10.40美元,一年高位為29.92美元。該公司的50日簡單移動均線切入位為20.72美元,200日簡單移動均線切入位為21.60美元。該股市值為10.8億美元,市盈率為-10.19倍,貝塔係數為1.86。

BioLife Solutions (NASDAQ:BLFS – Get Rating) last posted its quarterly earnings data on Wednesday, November 9th. The medical equipment provider reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03). BioLife Solutions had a negative net margin of 67.70% and a negative return on equity of 7.50%. The company had revenue of $40.75 million for the quarter, compared to analysts' expectations of $41.63 million. On average, analysts predict that BioLife Solutions, Inc. will post -0.63 EPS for the current year.
生物生命解決方案公司(納斯達克代碼:BLFS-GET Rating)最近一次公佈季度收益數據是在11月9日星期三。這家醫療設備提供商報告該季度每股收益(0.15美元),低於(0.03美元)(0.12美元)的普遍預期。BioLife Solutions的淨利潤率為負67.70%,股本回報率為負7.50%。該公司當季營收為4,075萬美元,高於分析師預期的4,163萬美元。分析師平均預測,BioLife Solutions,Inc.本年度每股收益將為0.63美元。

Insider Transactions at BioLife Solutions

BioLife Solutions的內幕交易

In related news, CMO Todd Berard sold 6,500 shares of BioLife Solutions stock in a transaction on Wednesday, January 18th. The shares were sold at an average price of $25.04, for a total value of $162,760.00. Following the transaction, the chief marketing officer now directly owns 119,265 shares in the company, valued at approximately $2,986,395.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, COO Greef Roderick De sold 20,000 shares of the firm's stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $23.86, for a total value of $477,200.00. Following the completion of the sale, the chief operating officer now directly owns 96,719 shares of the company's stock, valued at approximately $2,307,715.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Todd Berard sold 6,500 shares of the company's stock in a transaction on Wednesday, January 18th. The stock was sold at an average price of $25.04, for a total value of $162,760.00. Following the transaction, the chief marketing officer now directly owns 119,265 shares in the company, valued at approximately $2,986,395.60. The disclosure for this sale can be found here. Insiders sold 113,718 shares of company stock worth $2,466,734 over the last 90 days. 3.30% of the stock is currently owned by insiders.

在相關新聞中,首席營銷官託德·貝拉德在1月18日星期三的一次交易中出售了6,500股BioLife Solutions股票。這些股票的平均價格為25.04美元,總價值為162,760.00美元。交易完成後,首席營銷官現在直接持有該公司119,265股股票,價值約2,986,395.60美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可通過這個環節。在其他新聞方面,首席運營官格里夫·羅德里克·德在11月14日星期一的一筆交易中出售了20,000股公司股票。這隻股票的平均售價為23.86美元,總價值為477,200.00美元。出售完成後,首席運營官現在直接擁有該公司96,719股股票,價值約2,307,715.34美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可以通過這個環節。此外,首席營銷官託德·貝拉德在1月18日星期三的一次交易中出售了6500股公司股票。這隻股票的平均售價為25.04美元,總價值為162,760.00美元。交易完成後,首席營銷官現在直接持有該公司119,265股股票,價值約2,986,395.60美元。關於這次銷售的披露可以找到這裏。在過去的90天裏,內部人士出售了113,718股公司股票,價值2,466,734美元。3.30%的股份目前由內部人士持有。

Wall Street Analyst Weigh In

華爾街分析師也加入進來

Several equities analysts have issued reports on the stock. StockNews.com upgraded shares of BioLife Solutions to a "sell" rating in a research note on Monday, November 21st. Stephens dropped their price target on BioLife Solutions to $31.00 in a research note on Wednesday, November 16th.

幾位股票分析師已經發布了關於該股的報告。在11月21日星期一的一份研究報告中,StockNews.com將BioLife Solutions的股票評級上調至“賣出”。斯蒂芬斯在11月16日星期三的一份研究報告中將BioLife Solutions的目標價下調至31.00美元。

BioLife Solutions Company Profile

BioLife Solutions公司簡介

(Get Rating)

(獲取評級)

BioLife Solutions, Inc engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services.

BioLife Solutions,Inc.致力於細胞和組織生物保存工具的開發、製造和營銷。其產品包括用於細胞、組織和器官的專有低温儲存和冷凍保存冷凍介質產品,通用血液幹細胞冷凍和細胞解凍介質產品,以及定製產品配方和定製包裝服務。

Recommended Stories

推薦故事

  • Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
  • Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
  • Mullen Automotive Stock Gains Momentum On Positive News
  • Harley-Davidson Inc. Stock, Is It Time To Buy?
  • The Bottom Is In For Meta Platforms, Volatility Is Not Over
  • Analyzing Alaska Air's Recent Earnings
  • 免費獲取StockNews.com關於BioLife解決方案的研究報告(BLFS)
  • 凱西·伍茲的方舟創新ETF將在2023年反彈?
  • 馬倫汽車公司股票因利好消息而上漲
  • 哈雷-戴維森公司的股票,是時候買入了嗎?
  • Meta平臺的底部已經到了,波動性還沒有結束
  • 阿拉斯加航空公司近期收益分析

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

每日收到有關BioLife解決方案的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對BioLife Solutions和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論